StockNews.com Lowers Dyne Therapeutics (NASDAQ:DYN) to Sell

Dyne Therapeutics (NASDAQ:DYN) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday.

Several other analysts have also weighed in on DYN. JPMorgan Chase & Co. lifted their price objective on Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a report on Tuesday, July 9th. Guggenheim boosted their price target on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. Piper Sandler raised their price objective on shares of Dyne Therapeutics from $43.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Chardan Capital upped their target price on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, May 21st. Finally, HC Wainwright restated a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Stock Down 0.1 %

Shares of NASDAQ:DYN traded down $0.04 during trading on Tuesday, reaching $32.43. The stock had a trading volume of 1,435,324 shares, compared to its average volume of 1,613,956. The stock has a fifty day simple moving average of $41.48 and a two-hundred day simple moving average of $33.19. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -8.17 and a beta of 1.07. Dyne Therapeutics has a 52 week low of $6.40 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, analysts forecast that Dyne Therapeutics will post -2.96 EPS for the current year.

Insider Activity

In other news, CEO John Cox bought 32,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was purchased at an average price of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, COO Susanna Gatti High sold 29,787 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $35.01, for a total value of $1,042,842.87. Following the completion of the transaction, the chief operating officer now directly owns 148,792 shares in the company, valued at approximately $5,209,207.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John Cox bought 32,000 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now owns 8,000 shares in the company, valued at approximately $264,320. The disclosure for this purchase can be found here. Insiders sold a total of 79,950 shares of company stock valued at $2,736,302 in the last ninety days. 20.77% of the stock is owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new position in shares of Dyne Therapeutics during the 1st quarter worth approximately $140,666,000. Janus Henderson Group PLC increased its stake in Dyne Therapeutics by 23,512.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after buying an additional 2,663,910 shares during the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Dyne Therapeutics in the 4th quarter valued at $15,758,000. Price T Rowe Associates Inc. MD lifted its position in Dyne Therapeutics by 8,284.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after buying an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock worth $97,669,000 after buying an additional 1,110,629 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.